HK1010336A1 - Parathyroid hormone formulation - Google Patents

Parathyroid hormone formulation

Info

Publication number
HK1010336A1
HK1010336A1 HK98111127A HK98111127A HK1010336A1 HK 1010336 A1 HK1010336 A1 HK 1010336A1 HK 98111127 A HK98111127 A HK 98111127A HK 98111127 A HK98111127 A HK 98111127A HK 1010336 A1 HK1010336 A1 HK 1010336A1
Authority
HK
Hong Kong
Prior art keywords
parathyroid hormone
hormone formulation
excipient
buffering agent
formulation
Prior art date
Application number
HK98111127A
Other languages
English (en)
Inventor
Josephus Johannes Mar Holthuis
Albert Mekking
Alwinus Antonius Voetman
Original Assignee
Nps Allelix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nps Allelix Corp filed Critical Nps Allelix Corp
Publication of HK1010336A1 publication Critical patent/HK1010336A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK98111127A 1993-12-23 1998-10-08 Parathyroid hormone formulation HK1010336A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/172,206 US5496801A (en) 1993-12-23 1993-12-23 Parathyroid hormone formulation
PCT/CA1994/000693 WO1995017207A1 (en) 1993-12-23 1994-12-16 Parathyroid hormone formulation

Publications (1)

Publication Number Publication Date
HK1010336A1 true HK1010336A1 (en) 1999-06-17

Family

ID=22626763

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98111127A HK1010336A1 (en) 1993-12-23 1998-10-08 Parathyroid hormone formulation

Country Status (23)

Country Link
US (1) US5496801A (zh)
EP (2) EP0735896B1 (zh)
JP (1) JP3065662B2 (zh)
KR (1) KR100398461B1 (zh)
CN (1) CN1116897C (zh)
AT (1) ATE374621T1 (zh)
AU (1) AU681737B2 (zh)
BR (1) BR9408398A (zh)
CA (1) CA2179207C (zh)
CZ (1) CZ184296A3 (zh)
DE (1) DE69435033T2 (zh)
DK (1) DK0735896T3 (zh)
ES (1) ES2293637T3 (zh)
FI (1) FI120291B (zh)
HK (1) HK1010336A1 (zh)
HU (1) HUT74381A (zh)
LV (1) LV11731B (zh)
NO (1) NO324905B1 (zh)
NZ (1) NZ277463A (zh)
PL (1) PL315158A1 (zh)
PT (1) PT735896E (zh)
SK (1) SK82896A3 (zh)
WO (1) WO1995017207A1 (zh)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0131678B1 (ko) * 1991-12-09 1998-04-17 유미꾸라 레이이찌 파라티로이드 호르몬류의 안정화 조성물
US6509316B2 (en) * 1995-03-07 2003-01-21 George Washington University Pharmaceutical compositions, methods, and kits for treatment and diagnosis of lung cancer
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
WO1999004808A1 (fr) * 1997-07-22 1999-02-04 Chugai Seiyaku Kabushiki Kaisha Medicaments dentaires contenant de la pth
MY120063A (en) * 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
WO1999031137A1 (en) * 1997-12-18 1999-06-24 Eli Lilly And Company Crystalline teriparatide
SE9801495D0 (sv) * 1998-04-28 1998-04-28 Astra Ab Protein formulationa
AU1447600A (en) * 1998-10-22 2000-05-08 Thomas J. Gardella Bioactive peptides and peptide derivatives of parathyroid hormone (pth) and parathyroid hormone-related peptide (pthrp)
AU4217299A (en) 1998-11-30 2000-06-19 General Hospital Corporation, The Pth1r and pth3r receptors, methods and uses thereof
US6689566B1 (en) 1999-01-14 2004-02-10 Scantibodies Laboratory, Inc. Methods, kits, and antibodies for detecting parathyroid hormone
US7820393B2 (en) * 1999-01-14 2010-10-26 Scantibodies Laboratory, Inc. Methods, kits and antibodies for detecting parathyroid hormone
US7893021B2 (en) * 1999-06-02 2011-02-22 Scantibodies Laboratory, Inc. Parathyroid hormone antagonists and uses thereof
US20080108086A1 (en) * 1999-06-02 2008-05-08 Cantor Thomas L Parathyroid hormone antagonists and uses thereof
CA2378949C (en) * 1999-07-12 2015-03-31 Grandis Biotech Gmbh Growth hormone formulations
AU7734800A (en) * 1999-09-29 2001-04-30 General Hospital Corporation, The Polypeptide derivatives of parathyroid hormone (pth)
WO2001056594A1 (en) 2000-02-04 2001-08-09 Unigene Laboratories, Inc. Nasal calcitonin formulations
CA2380423A1 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
US6905886B2 (en) * 2000-08-11 2005-06-14 Quest Diagnostics Investments Incorporated Preservative solutions
US6387711B1 (en) * 2000-08-11 2002-05-14 Quest Diagnostics Investments Incorporated Liquid intact parathyroid hormone (PTH) standards
AU2002211629A1 (en) * 2000-10-10 2002-04-22 Microchips, Inc. Microchip reservoir devices using wireless transmission of power and data
KR100491737B1 (ko) * 2001-07-20 2005-05-27 주식회사 한국아이템개발 공기 정화 기능의 모기 퇴치기
JP4837888B2 (ja) 2001-07-23 2011-12-14 ザ ジェネラル ホスピタル コーポレイション コンホメーションが拘束された副甲状腺ホルモン(pth)類似体
US7497855B2 (en) * 2002-09-04 2009-03-03 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
US20040067526A1 (en) * 2002-10-03 2004-04-08 Cantor Thomas L. Methods for diagnosing and guiding treatment of bone turnover disease
US7795220B2 (en) * 2003-03-19 2010-09-14 The General Hospital Corporation Conformationally constrained parathyroid hormones with alpha-helix stabilizers
ES2437565T3 (es) * 2003-06-30 2014-01-13 Alza Corporation Formulaciones para microproyecciones revestidas que contienen contraiones no volátiles
KR100540659B1 (ko) * 2003-07-02 2006-01-10 삼성전자주식회사 이미지 확대 인쇄 방법과 장치 및 컴퓨터 프로그램을저장하는 컴퓨터로 읽을 수 있는 기록 매체
WO2005014034A1 (en) * 2003-07-14 2005-02-17 Nps Allelix Corp. Stabilized formulation of parathyroid hormone
EP1653985A4 (en) 2003-07-17 2009-08-05 Gen Hospital Corp CONSTRAINTS CONTAINING CONTAINING HORMONE PARATHYROID (PTH) ANALOGUES
US7459276B2 (en) * 2003-09-29 2008-12-02 Scantibodies Laboratory, Inc. Methods and controls for monitoring assay quality and accuracy in parathyroid hormone measurement
US20050119183A1 (en) * 2003-11-12 2005-06-02 Nps Allelix Corp. Method for treating bone loss using parathyroid hormone
AU2004292954A1 (en) * 2003-11-13 2005-06-09 Alza Corporation Composition and apparatus for transdermal delivery
CN100406059C (zh) * 2004-04-30 2008-07-30 陈新梅 甲状旁腺激素的新用途
ES2568259T3 (es) * 2004-05-13 2016-04-28 Alza Corporation Aparato y método para la administración transdérmica de agentes de hormona paratiroidea
US7541140B2 (en) * 2004-06-03 2009-06-02 Scantibodies Laboratory, Inc. Assessing risk for kidney stones using parathyroid hormone agonist and antagonist
US20080076975A1 (en) * 2005-01-25 2008-03-27 Microchips, Inc. Method and implantable device with reservoir array for pre-clinical in vivo testing
WO2006081279A2 (en) * 2005-01-25 2006-08-03 Microchips, Inc. Control of drug release by transient modification of local microenvironments
KR100700869B1 (ko) 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Pth, 완충제 및 안정제를 포함하는 안정한 pth조성물
WO2007059470A2 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2008019062A2 (en) * 2006-08-04 2008-02-14 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (pth)
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
AU2008282805B2 (en) 2007-08-01 2014-05-01 Chugai Pharmaceutical Co., Ltd. Screening methods using G-protein coupled receptors and related compositions
EP2173768B1 (en) * 2007-08-09 2014-03-05 USV Limited Novel orthogonal process for purification of recombinant human parathyroid hormone (rhpth) (1-34)
JP2009091363A (ja) * 2008-11-21 2009-04-30 Asahi Kasei Pharma Kk Pthの安定化水溶液注射剤
JP2013512688A (ja) 2009-12-07 2013-04-18 ミシガン テクノロジカル ユニバーシティ クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
BR112012028949B1 (pt) 2010-05-13 2020-11-17 Chugai Seiyaku Kabushiki Kaisha polipeptídeo análogo do hormônio paratireoideo, seu uso e método de produção, bem como ácido nucleico, vetor de expressão, célula e composição farmacêutica
BR112013023062B1 (pt) * 2011-03-10 2022-01-18 Xeris Pharmaceuticals, Inc Solução estável para a injeção parenteral e método de fabricação da mesma
CN103561757B (zh) 2011-06-07 2016-01-06 旭化成制药株式会社 高纯度含pth冷冻干燥制剂及其制造方法
CN105025928A (zh) * 2013-03-15 2015-11-04 普西维达公司 用于递送治疗剂的可生物蚀解的硅基组合物
CN103301058A (zh) * 2013-06-17 2013-09-18 深圳翰宇药业股份有限公司 一种特立帕肽注射用组合物及其制备方法和制剂
CA3107105A1 (en) * 2018-07-30 2020-02-06 Shire-Nps Pharmaceuticals, Inc. Formulations for improved stability of recombinant human parathyroid hormone
CN110917150A (zh) * 2019-12-31 2020-03-27 北京博康健基因科技有限公司 一种pth冻干制剂及其制备方法
US20230190880A1 (en) * 2020-03-30 2023-06-22 Sichuan Luzhou Buchang Bio-Pharmaceutical Co., Ltd. Formulations of Human Parathyroid Hormone (PTH) and Methods for Producing Same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3768177A (en) * 1972-08-02 1973-10-30 R Thomas Educational device
US4105602A (en) * 1975-02-10 1978-08-08 Armour Pharmaceutical Company Synthesis of peptides with parathyroid hormone activity
US4016314A (en) * 1975-06-26 1977-04-05 Hallco Inc. Embroidered fruit bowl wall hanging and kit for making same
US4199060A (en) * 1978-07-20 1980-04-22 Howard Hardware Products, Inc. Lock installation kit
US4424278A (en) * 1981-11-16 1984-01-03 Research Corporation Cancer detection procedure using an acyl carrier protein
JPS61267528A (ja) * 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
US4812311A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
JPS6360940A (ja) * 1986-09-01 1988-03-17 Toyo Jozo Co Ltd 白内障の予防または治療剤
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
US5011678A (en) * 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
DE3935738A1 (de) * 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
GB9020544D0 (en) * 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
JP3090353B2 (ja) * 1991-09-17 2000-09-18 旭化成工業株式会社 パラチロイドホルモン類含有経鼻投与用乳剤
KR0131678B1 (ko) * 1991-12-09 1998-04-17 유미꾸라 레이이찌 파라티로이드 호르몬류의 안정화 조성물
SK74594A3 (en) * 1991-12-17 1995-01-12 Procter & Gamble Pharma Treatment for treating of osteoporosis
IT1255723B (it) * 1992-10-09 1995-11-13 Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione

Also Published As

Publication number Publication date
BR9408398A (pt) 1997-08-12
LV11731A (lv) 1997-04-20
EP0735896A1 (en) 1996-10-09
NO324905B1 (no) 2007-12-27
NO962634L (no) 1996-06-20
DK0735896T3 (da) 2008-02-04
FI962593A0 (fi) 1996-06-20
EP1880732A1 (en) 2008-01-23
CN1142772A (zh) 1997-02-12
ES2293637T3 (es) 2008-03-16
PL315158A1 (en) 1996-10-14
DE69435033T2 (de) 2008-05-29
FI962593A (fi) 1996-08-19
NO962634D0 (no) 1996-06-20
AU681737B2 (en) 1997-09-04
ATE374621T1 (de) 2007-10-15
JP3065662B2 (ja) 2000-07-17
HUT74381A (en) 1996-12-30
CZ184296A3 (en) 1997-01-15
CA2179207A1 (en) 1995-06-29
CA2179207C (en) 2000-11-14
PT735896E (pt) 2007-12-07
SK82896A3 (en) 1997-01-08
EP0735896B1 (en) 2007-10-03
DE69435033D1 (de) 2007-11-15
NZ277463A (en) 1997-03-24
HU9601721D0 (en) 1996-08-28
CN1116897C (zh) 2003-08-06
AU1269895A (en) 1995-07-10
FI120291B (fi) 2009-09-15
LV11731B (en) 1997-08-20
KR100398461B1 (ko) 2004-03-20
US5496801A (en) 1996-03-05
JPH09506869A (ja) 1997-07-08
WO1995017207A1 (en) 1995-06-29

Similar Documents

Publication Publication Date Title
HU9601721D0 (en) Parathyroid hormone formulation
EP0619119A4 (en) COMPOSITION BASED ON STABILIZED PARATHYROIDIAN HORMONE.
EP0607325A4 (en) Parathyroid hormone analogues substituted at aa?25,26,27 and use in osteoporosis treatment.
ES2055845T3 (es) Composicion farmaceutica para el tratamiento de la osteoporosis.
UA72884C2 (uk) Стабілізовані розчини паратирину
IE882671L (en) Stabilised human protein formulation
HUT68525A (en) Pharmaceutical compositions of prolonged delivery, containing peptides
GR900300006T1 (en) Intravaginal delivery of biologically active polypeptides
NZ230280A (en) Pharmaceutical formulation containing an insulin derivative modified with a base, with an isoelectric point between 5.8 - 8.5, and with a zinc ion content of from 2mug - 200mug of zinc/iu
IL140140A0 (en) Thyroid hormone analogues and methods for their preparation
HU9302971D0 (en) Chewable antacid preparations
ZA934037B (en) Novel biologically active eburnamenine derivatives, pharmaceutical compositions containing them and process for preparing same.
GB2251188B (en) Drug delivery system comprising a lysophosphoglycerolipid
IL87778A0 (en) Pharmaceutical compositions containing stabilized therapeutically active proteins and their preparation
IL92061A0 (en) Pharmaceutical compositions containing biologically active peptides and certain anions
AU4685389A (en) Pharmaceutical compositions and use thereof in the treatment of psoriasis
IL103862A (en) Stabilized pharmaceutical composition of non-glycosylated recombinant human IL2 in reduced form and its preparation process
ZA939566B (en) Method for dry blend compression od medicaments.
EP0175323A3 (en) Biologically active peptides, processes for preparing them and pharmaceutical compositions

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20141215